Strides Pharma Science Ltd · NSE:STAR
Strides Pharma Science — Q2 FY2023 Earnings Presentation
18 slides from Strides Pharma Science's earnings presentation, Nov 14, 2022
Slide 1: Q2FY23 Earnings Update
Q2FY23 Earnings Update Strides Pharma Science Limited November 14, 2022
Slide 2: Strides reports improved Q2FY23 results led by 690bps gross margin expansion
Strides reports improved Q2FY23 results led by 690bps gross margin expansion; returns to positive adjusted PAT Quarterly Performance (₹m) Particulars Q2 FY23 Q1 FY23 Q2 FY22 QoQ YoY We continue to make good strategic progress across all our key businesses with a sharper focus on execution and cost c
Slide 3: Q2FY23 reported revenues up 22% YoY with US business reporting best ever quarter
Q2FY23 reported revenues up 22% YoY with the US business reporting its best ever quarterly performance Market Wise Performance- Quarter on Quarter (₹m) Particulars Q2 FY23 Q1 FY23 Q2 FY22 QoQ YoY ▸ US revenues at ₹4,726m ($60m) for Q2FY23, up from ₹3,552m ($46m) in Q1FY23 and ₹2,502m ($34m) US busin
Slide 4: Market Wise Outlook
Market Wise Outlook
Slide 5: US Business reports its best-ever quarterly performance at $60m revenues
US Business reports its best-ever quarterly performance at $60m revenues US Revenues - Quarterly Trend ($m) Quarterly Updates and Business Outlook • Revenues from the US for Q2FY23 stood at ₹4,726 ($60m), up 33% QoQ and 89% YoY, 58 60 representing 52% of consolidated revenues for Q2FY23. 54 55 50 •
Slide 6: Exit of low margin businesses led to sequential decline in Other Regulated Markets
Exit of low margin businesses led to sequential decline in Other Regulated Markets (ORM) revenues Expect the business to attain its historical levels with superior margins starting Q3FY23 ORM Revenues - Quarterly Trend ($m) Business updates • Revenues from the ORM for Q2FY23 stood at ₹2,414 m ($31m)
Slide 7: Emerging and Access markets impacted by lower off take for the tender business
Emerging and Access markets impacted by lower off take for the tender business, branded business delivers steady performance EM Revenues - Quarterly Trend ($m) Business updates • Revenues from the Emerging and Access Markets for Q2FY23 stood at ₹1,855 m ($23m), 37 versus $2,858 m($37m) in Q1FY23 and
Slide 8: Financial Performance
Financial Performance
Slide 9: Key P&L Highlights – Q2 FY23
Key P&L Highlights – Q2 FY23 Income statement (₹m) Particulars Q2 FY23 Q1 FY23 Q2 FY22 QoQ YoY Revenues 8,995 9,457 7,360 -5% 22% EBITDA 1,006 657 10 53% 100+% EBITDA % 11.2% 6.9% 0.1% 430bps 1,110bps Reconciliation of EBITDA (₹m) As per SEBI results Q2 FY23 Q1 FY23 Q2 FY22 Profit before exceptional
Slide 10: Details on Non-operational items in Q2FY23
Details on Non-operational items in Q2FY23 Exceptional items in P&L for Q1 FY23 (₹m) Particulars Description Q2FY23 Exchange Gain / (Loss) Relating to long term loans and deferred consideration -463 Product recall & Inventory provision Past recall and Inventory provisions -151 Severance Severance an
Slide 11: Arrow deferred consideration to be received; H2 focus on free cash generation
Arrow deferred consideration to be received ahead of contractual obligation; H2 focus will be on free cash generation for right-sizing working capital; On target to bring down Net Debt to exit FY23 EBITDA under 3 Debt book Outlook Particulars ₹m* Debt reduction initiatives planned for FY23 Term Loan
Slide 12: Update on Stelis Biopharma
Update on Stelis Biopharma
Slide 13: With regulatory approvals from USFDA and EMA, Stelis CDMO business is moving forward
With regulatory approvals from USFDA and EMA, Stelis CDMO business is moving forward positively A high capital long gestation investment ready to achieve growth and profitability • Stelis has emerged as a biopharmaceutical company with integrated capabilities in developing, scale-up, and commercial
Slide 14: CDMO Business: Order traction improving as new Global partners are onboarded
CDMO Business: The order traction is improving as new Global partners are being onboarded to Stelis Key updates for the quarter Near Term Outlook • Stelis onboarded three new Global partners with its first-ever • Ongoing discussions with new major big pharma companies to offer external contract for
Slide 15: Biolexis: First biosimilar rh-teriparatide received positive recommendation from EMA
Biolexis: Our first biosimilar- rh-teriparatide has received positive recommendation from EMA Key updates for the quarter Near Term Outlook • STLP001 (PTH or brand name KaulivTM) has received a positive recommendation • Stelis has already licensed KaulivTM across 20 countries and the from the Europe
Slide 16: Earnings Call Details
Earnings Call Details
Slide 17: Strides Pharma Science Ltd – Q2FY23 Earnings Call
Strides Pharma Science Ltd – Q2FY23 Earnings Call invites you to interact with the senior management on Q2FY23 Click on the icon above to pre-register and join without the operator November 14, 2022 5:00pm IST / 12:30pm BST / 6:30am ET / 7:30pm HKT Join through an operator using dial in numbers Indi
Slide 18: Thank You
Thank You Strides Pharma Science Limited CIN: L24230MH1990PLC057062 REGISTERED OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924/ 2789 3199 Fax: +91 22 2789 2942 Email: corpcomm@strides.com Website: www.strides.com CORPORATE OFFICE Strides House, Bilekahalli
Strides Pharma Science — Q2 FY2023 Earnings Presentation on 6ix